Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Corporate Update (February 2015)
32 slides from Matinas Biopharma's corporate update, Feb 2, 2015
Slide 1: Business Update Conference Call
OTCQB: MTNB BUSINESS UPDATE CONFERENCE CALL February 2, 2015 www.MatinasBioPharma.com A clinical - stage biopharmaceutical company focused on the development of lipid - based prescription therapeutics for the treatment of cardiovascular and metabolic conditions and infectious diseases 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other st
Slide 3: Agenda
Agenda • MATINAS BIOPHARMA AND AQUARIUS SYNERGIES AND STRATEGY Roelof Rongen , Chief Executive Officer and Co - Founder • TECHNOLOGY, SCIENTIFIC PARTNERS, MATINAS BIOPHARMA Dr . Raphael J. Mannino , F ounder of Aquarius and an Inventor of the C ochleate B io - delivery Platform Technology • TRANSACT
Slide 4: Matinas BioPharma and Aquarius Biotechnologies Synergies and Strategy
4 Roelof Rongen Matinas BioPharma and Aquarius Biotechnologies S ynergies and Strategy
Slide 5: Aquarius Biotechnologies Highlights
Aquarius Biotechnologies Highlights • Novel lipid - crystal nano - particle cochleate formulation delivery platform with opportunity for broad use in anti - infectives • Proprietary technology platform with broad application expected to drive a robust pipeline in high - value markets and niche, pote
Slide 6: Synergistic Lipid-Based Therapy Approach
Synergistic Lipid - Based Therapy Approach Lipid - Based Therapies Lipids as Pharmaceutically Active Compounds ▪ MAT9001 • Severe hypertriglyceridemia • Other dyslipidemia ▪ MAT8800 • Fatty Liver Disease Lipids as “ Nano - Particle” Delivery Vehicles ▪ MAT2203 – C - Amphotericin B • Broad Spectrum F
Slide 7: Pipeline Expansion with Additional Clinical-Stage Opportunities
P ipeline Expansion with Additional Clinical - Stage Opportunities with Potential to Drive Sustainable Value Discovery IND Preparation Early Clinical Development Phase 3 Development MAT9001 MAT2203 MAT2501 MAT8800 Severe Hypertriglyceridemia Fungal Infections Gram - Negative Bacterial Infections Fat
Slide 8: MAT9001 A Next Generation Prescription-only Omega-Fatty Acid Medication
8 MAT9001 A Next Generation Prescription - only Omega - 3 Fatty Acid Medication
Slide 9: MAT9001 – Program Achievements
MAT9001 – Program Achievements x Promising results with DPA in pre - clinical studies x Proprietary process for high purity DPA manufacturing, at GMP 10+kg scale x Development of proprietary soft - gel formulation x Formation of prominent Scientific Advisory Board x Filed MAT9001 IND with FDA Q4 201
Slide 10: Lead Product Candidate MAT9001 Remains a Priority
Lead Product Candidate MAT9001 Remains a Priority Discovery IND Preparation Early Clinical Development Phase 3 Development MAT9001 Next Steps: • Comparative PK/PD crossover study ongoing in Canada – ~50 pts • Protocol responses to FDA (comparative PK and animal tox ) • Conduct comparative PK and ani
Slide 11: MAT2203 Amphotericin B Delivered in a Lipid-Crystal Nano-Particle Cochleate Formulation
11 MAT2203 Amphotericin B Delivered in a Lipid - Crystal Nano - Particle Cochleate Formulation -- Broad - Spectrum Fungicidal Agent --
Slide 12: Cochleate Technology Offers Significant Clinical Improvement Potential
Cochleate Technology Offers S ignificant C linical I mprovement P otential Multi - Organ Protection • Cochleates act as a shield for the body from otherwise toxic medicinal compounds Targeted Delivery • Cochleates are carried directly to infection sites Oral Administration • Efficacy demonstrated in
Slide 13: Cochleate Targeted Nano-particle Delivery Mitigates the Limitations of Amphotericin B
Cochleate Targeted Nano - particle Delivery Mitigates the Limitations of Amphotericin B 50 - 500 nm * Phosphatidylserine PS* Bilayer Calcium Drug 1. Reduces toxicity by containing drug inside particle 2. Size and surface features facilitate targeted delivery 3. Potential for oral administration High
Slide 14: Scientific Merit of Cochleate Technology Has Led to Several NIH Collaborations
Scientific Merit of Cochleate Technology and Clinical Unmet Need has Led to Several NIH Collaborations • NIH SBIR grants and research contracts towards encochleated Amphotericin B research • NIH SBIR grants and research contracts toward encochleated Aminoglycoside antibiotics research – Amikacin – C
Slide 15: MAT2203 – Recent Significant Advancements
MAT2203 – Recent Significant Advancements x Completed c ryptococcal meningitis mouse studies at NIH with C - Amphotericin B x Increasing C - Amphotericin B scale to ~800 doses/batch x Preparing for C - Amphotericin B Phase 2a efficacy trial at NIH – refractory mucocutaneous candidiasis patients 15
Slide 16: Invasive Fungal Infections: Significant Clinical Need for Fungicidal Agents
Invasive Fungal Infections x Cryptococcal Meningoencephalitis x Aspergillosis Significant Clinical Need for Fungicidal Agents Hematological Malignancies x Leukemias • ALL • AML Stem Cell Transplants x Autologous x Allogeneic Solid Organ Transplants x Kidney x Liver x Other Approximately 150,000 pote
Slide 17: MAT2203 – Development Overview
MAT2203 – Development Overview Discovery IND Preparation Early Clinical Development Phase 3 Development MAT2203 Next Steps: x Single - Dose Phase 1 study completed ▪ Patient treatment protocols under development in collaboration with NIH/NIAID ▪ Phase 2a study expected to commence in 1H 2015 17
Slide 18: MAT2501 Amikacin Delivered in a Lipid-Crystal Nano-Particle Cochleate Formulation
18 MAT2501 Amikacin Delivered in a Lipid - Crystal Nano - Particle Cochleate Formulation -- Gram - Negative Aminoglycoside Antibiotic --
Slide 19: MAT2501 – Development Overview
MAT2501 – Development Overview MAT2501 – C - Amikacin Treating severe and hospital - acquired gram - negative bacterial infections Potential High - need Indications: • Cystic Fibrosis pulmonary infections • Ventilated patients in ICU or long - term care • Hospital acquired urinary track infections D
Slide 20: Cochleate Nanoparticle Delivery Has Broad Utility
Cochleate Nanoparticle Delivery has Broad Utility with Potential for Orphan Drug Applications Collaborations In - Vitro Animal POC IND - Prep Human Studies Amphotericin B NIH / PHRI Amikacin NIH Vaccines Ibuprofen Atovaquone NIH Capreomycin NIH Meropenem NIH Curcumin Omega - 3 FA 20
Slide 21: Anti-Infective Companies Garner Significant Value
Anti - Infective Companies Garner Significant Value Company Lead Program Indication Clinical Phase Share Price* Market Cap* Achaogen (AKAO) plazomicin Serious bacterial infections due to Multi - Drug - Resistant Enterobacteriaceae Phase 3 $11.77 $209M Cempra (CEMP) Solithromycin Pneumonia (CABP) and
Slide 22: Recently Materialized Transactions Validate Potential in Anti-Infectives Space
Recently Materialized Transactions Validate Potential in Anti - I nfectives Space Recent Acquisitions in Antibiotics Date Company Acquirer Lead Program Indication Stage at time of deal Deal Total 12/14 Cubist Merck Multiple Anti - infectives Multiple Launched/ Approved/ Phase 3 $9.5B 11/14 Durata Th
Slide 23: MAT8800 Fatty Liver Disease Discovery Program
23 MAT8800 Fatty Liver Disease Discovery Program
Slide 24: MAT8800 – Development Overview
MAT8800 – Development Overview MAT8800 – Proprietary Omega - 3 Discovery Program Treating Fatty Liver Disease NAFLD NASH • Common: 12% of U.S. population • A leading cause of cirrhosis • NO APPROVED TREATMENT OPTION Discovery IND Preparation Early Clinical Development Phase 3 Development MAT8800 Nex
Slide 25: Experienced Management Team and Board
Experienced Management Team and Board Roelof Rongen – President and CEO, Director George Bobotas , PhD – Chief Scientific Officer Jerome Jabbour , JD – Chief Business Officer & General Counsel Abdel Fawzy , PhD – EVP Pharmaceutical & Supply Chain Dev. Gary Gaglione, CPA – VP Finance, Acting CFO Herb
Slide 26: Prominent Scientific Advisory Board
Dyslipidemia & Cardiovascular Diseases Christie M. Ballantyne, MD, PhD, FACC, FNLA – Baylor College of Medicine , Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center, Lipid Metabolism and Atherosclerosis Clinic at Houston Methodist Hospital Kevin Maki, PhD
Slide 27: Technology, Scientific Partners, Matinas BioPharma
27 Raphael Mannino , Ph.D. Technology, Scientific Partners, Matinas BioPharma
Slide 28: Transaction Summary and Financial Update
28 Jerry Jabbour Transaction Summary and Financial Update
Slide 29: Q&A
29 Q&A
Slide 30: Closing Comments
30 Roelof Rongen Closing Comments
Slide 31: MTNB Represents a Compelling Investment Opportunity
MTNB Represents a Compelling I nvestment O pportunity x Unique and differentiated expertise in lipidomics , lipid chemistry and lipid - based delivery x Phase 2a and Phase 3 clinical development programs expected to commence in 2015 x Novel technology platform with broad application expected to driv
Slide 32: Business Update Conference Call
OTCQB: MTNB BUSINESS UPDATE CONFERENCE CALL February 2, 2015 www.MatinasBioPharma.com A clinical - stage biopharmaceutical company focused on the development of lipid - based prescription therapeutics for the treatment of cardiovascular and metabolic conditions and infectious diseases 32
Matinas BioPharma Holdings — Corporate Update (February 2015) on 6ix